- Home
- OMAB vs ADMA Comparison
OMAB vs ADMA Comparison
Compare OMAB & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMAB
- ADMA
- Stock Information
- Founded
- OMAB 1998
- ADMA 2004
- Country
- OMAB Mexico
- ADMA United States
- Employees
- OMAB N/A
- ADMA N/A
- Industry
- OMAB Aerospace
- ADMA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- OMAB Consumer Discretionary
- ADMA Health Care
- Exchange
- OMAB Nasdaq
- ADMA Nasdaq
- Market Cap
- OMAB 3.8B
- ADMA 4.1B
- IPO Year
- OMAB 2006
- ADMA N/A
- Fundamental
- Price
- OMAB $83.53
- ADMA $21.31
- Analyst Decision
- OMAB Buy
- ADMA Strong Buy
- Analyst Count
- OMAB 2
- ADMA 4
- Target Price
- OMAB $99.00
- ADMA $22.50
- AVG Volume (30 Days)
- OMAB 89.7K
- ADMA 3.7M
- Earning Date
- OMAB 04-28-2025
- ADMA 05-08-2025
- Dividend Yield
- OMAB 5.77%
- ADMA N/A
- EPS Growth
- OMAB N/A
- ADMA N/A
- EPS
- OMAB 0.61
- ADMA 0.81
- Revenue
- OMAB $723,360,685.00
- ADMA $426,454,000.00
- Revenue This Year
- OMAB $0.77
- ADMA $18.45
- Revenue Next Year
- OMAB $13.57
- ADMA $26.96
- P/E Ratio
- OMAB $16.48
- ADMA $26.31
- Revenue Growth
- OMAB 4.26
- ADMA 65.16
- 52 Week Low
- OMAB $59.08
- ADMA $6.01
- 52 Week High
- OMAB $90.53
- ADMA $23.64
- Technical
- Relative Strength Index (RSI)
- OMAB 60.63
- ADMA 60.16
- Support Level
- OMAB $79.94
- ADMA $17.30
- Resistance Level
- OMAB $83.24
- ADMA $22.25
- Average True Range (ATR)
- OMAB 3.47
- ADMA 1.50
- MACD
- OMAB 0.48
- ADMA 0.16
- Stochastic Oscillator
- OMAB 93.72
- ADMA 83.62
About OMAB Grupo Aeroportuario del Centro Norte S.A.B. de C.V. ADS
Grupo Aeroportuario del Centro Norte SAB de CV operates airports in the central region of Mexico. The airport is in Monterrey, which serves nearly half of the company's total passengers. In addition, the company manages two hotels and one industrial park.
About ADMA ADMA Biologics Inc
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.